Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Li Zhang(State Key Laboratory of Oncology in South China), Yan Huang(Sun Yat-sen University), Shaodong Hong(State Key Laboratory of Oncology in South China), Yunpeng Yang(Sun Yat-sen University Cancer Center), Gengsheng Yu(Jiangmen Central Hospital), Jun Jia(Dongguan People’s Hospital), Peijian Peng(Sun Yat-sen University), Xuan Wu(Sun Yat-sen University Cancer Center), Qing Lin(The First People's Hospital of Shunde), Xuping Xi(Hunan Cancer Hospital), Jiewen Peng(Zhongshan People's Hospital), Mingjun Xu, Dongping Chen(Guangzhou Medical University), Xiaojun Lu(Zhongshan People's Hospital), Rensheng Wang(First Affiliated Hospital of GuangXi Medical University), Xiaolong Cao(Panyu District Central Hospital), Xiaozhong Chen(Zhejiang Cancer Hospital), Zhixiong Lin(Shantou University), Jianping Xiong(First Affiliated Hospital of Nanchang University), Qin Lin(First Affiliated Hospital of Xiamen University), Conghua Xie(Zhongnan Hospital of Wuhan University), Zhihua Li(Sun Yat-sen University), Jianji Pan(Fujian Provincial Cancer Hospital), Jingao Li(Jiangxi Provincial Cancer Hospital), Shixiu Wu(Hangzhou Cancer Hospital), Yingni Lian(The First People's Hospital of Zhaoqing), Quanlie Yang(Meizhou City People's Hospital), Chong Zhao(Sun Yat-sen University Cancer Center)
The Lancet
August 25, 2016
Cited by 525

Abstract


Related Papers

No related papers found

Powered by citation graph analysis